News headlines about Odonate Therapeutics (NASDAQ:ODT) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Odonate Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.8456190020153 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several brokerages have weighed in on ODT. Goldman Sachs Group began coverage on Odonate Therapeutics in a report on Tuesday, January 2nd. They issued a “neutral” rating and a $27.00 target price for the company. Jefferies Group began coverage on Odonate Therapeutics in a report on Tuesday, January 2nd. They issued a “buy” rating and a $40.00 target price for the company. Finally, Cowen began coverage on Odonate Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating for the company.

Shares of Odonate Therapeutics (NASDAQ ODT) traded down $0.18 during midday trading on Friday, hitting $23.51. The company had a trading volume of 35,700 shares, compared to its average volume of 39,838. The stock has a market cap of $636.23 and a PE ratio of -33.11. Odonate Therapeutics has a 1 year low of $22.31 and a 1 year high of $25.36.

In related news, Director Boxer Capital, Llc acquired 416,666 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The stock was purchased at an average cost of $24.00 per share, for a total transaction of $9,999,984.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kevin C. Tang acquired 1,291,666 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were bought at an average price of $24.00 per share, with a total value of $30,999,984.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,709,332 shares of company stock valued at $41,023,268 over the last 90 days.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/odonate-therapeutics-odt-earns-daily-media-impact-rating-of-0-20/1804362.html.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc, formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.